Evidence map›Paper›PMID 37724076›Full record

ReviewMedical review (2021)2021

A novel function of CREG in metabolic disorders.

Yang Li, Xiaoxiang Tian, Quanyu Zhang, Chenghui Yan, Yaling Han

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Medical review (2021), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Nutrients · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yang LiCardiovascular Research Institute and Department of Cardiology, General Hospital of Northern Theater Command, Shenyang 110016, Liaoning, China.
Xiaoxiang TianCardiovascular Research Institute and Department of Cardiology, General Hospital of Northern Theater Command, Shenyang 110016, Liaoning, China.
Quanyu ZhangCardiovascular Research Institute and Department of Cardiology, General Hospital of Northern Theater Command, Shenyang 110016, Liaoning, China.
Chenghui YanCardiovascular Research Institute and Department of Cardiology, General Hospital of Northern Theater Command, Shenyang 110016, Liaoning, China.
Yaling HanCardiovascular Research Institute and Department of Cardiology, General Hospital of Northern Theater Command, Shenyang 110016, Liaoning, China.ORCID https://orcid.org/0000-0001-6390-6991

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic disorders are public health problems that require prevention and new efficient drugs for treatment. Cellular repressor of E1A-stimulated genes (CREG) is ubiquitously expressed in mature tissues and cells in mammals and plays a critical role in keeping cells or tissues in a mature, homeostatic state. Recently, CREG turns to be an important mediator in the development of metabolic disorders. Here in this review, we briefly discuss the structure and molecular regulation of CREG along with the therapeutic strategy to combat the metabolic disorders.

Indexed as

CREGinsulin resistancemetabolic disordersNAFLDobesityskeletal muscle energy metabolism

Identifiers

PMID37724076
PMCPMC10388757

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.